Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Public ClinicalTrials.gov record NCT01226745. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this active-drug Extension Study is to evaluate the continuing safety and efficacy of ONO-4641 (MSC2430913A) in subjects with relapsing-remitting multiple sclerosis (RRMS) who have completed an initial 26-week Core Study (ONO-4641POU006 \[NCT01081782\]).
Study identification
- NCT ID
- NCT01226745
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 340 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2010
- Primary completion
- Dec 31, 2014
- Completion
- Dec 31, 2014
- Last update posted
- Jul 11, 2016
2010 – 2015
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Tucson Clinical Site 133 | Tucson | Arizona | 85705 | — |
| Aurora Clinical Site 132 | Aurora | Colorado | 80045 | — |
| Fort Collins Clinical Site 123 | Fort Collins | Colorado | 80528 | — |
| Fairfield Clinical Site 110 | Fairfield | Connecticut | 06824 | — |
| Ormond Beach Clinical Site 129 | Ormond Beach | Florida | 32174 | — |
| Sarasota Clinical Site 116 | Sarasota | Florida | 34243 | — |
| Northbrook Clinical Site 135 | Northbrook | Illinois | 60062 | — |
| Fort Wayne Clinical Site 111 | Fort Wayne | Indiana | 46805 | — |
| Indianapolis Clinical Site 121 | Indianapolis | Indiana | 46202 | — |
| Detroit Clinical Site 104 | Detroit | Michigan | 48202 | — |
| Farmington Hills Clinical Site 126 | Farmington Hills | Michigan | 48334 | — |
| Lebanon Clinical Site 115 | Lebanon | New Hampshire | 03756 | — |
| Albuquerque Clinical Site 106 | Albuquerque | New Mexico | 87131 | — |
| Rochester Clinical Site 108 | Rochester | New York | 14642 | — |
| Charlotte Clinical Site 125 | Charlotte | North Carolina | 28201 | — |
| Raleigh Clinical Site 103 | Raleigh | North Carolina | 27607 | — |
| Akron Clinical Site 112 | Akron | Ohio | 44320 | — |
| Philadelphia Clinical Site 120 | Philadelphia | Pennsylvania | 19104 | — |
| Knoxville Clinical Site 134 | Knoxville | Tennessee | 37934 | — |
| Round Rock Clinical Site 107 | Round Rock | Texas | 78681 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01226745, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 11, 2016 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01226745 live on ClinicalTrials.gov.